UK veterinary group operating a network of veterinary practices, diagnostic labs and an online pet pharmacy.
UK veterinary group operating a network of veterinary practices, diagnostic labs and an online pet pharmacy.
Earns fees from consultations, surgery and treatment at its own practices, plus sales of medicines and pet food, with in-house diagnostic labs adding margin. Growth comes from buying independent practices, and the group has been under a regulator review of UK vet pricing since 2024.
In one line: A UK Mars Veterinary Health/IVC Evidensia peer.
Moat: narrow (scale, brand, distribution). Consolidated network of vet practices with in-house diagnostics builds referral scale.
Headquarters: Diss, UK · Founded: 1999
Size CVS (CVSG.L) is a United Kingdom Health Care company (Hospital/Nursing Management) with a market value of $1.22B, the 204th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £1,400 on 18 Nov 2026.
Performance Over six months the shares gained 16.8%, against -3.8% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 5.9% over the last twelve months (peer median +13.8%); the operating margin is 10.6% (peer median 10.0%).
Valuation It trades at 14.6× forward earnings against a peer median of 30.6× (2nd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.0 points below its cost of capital (10.4% WACC).
Credit CVS has 2 bonds outstanding ($767M), rated BBB by the agencies and trading like A- at a weighted spread of 115 bp.
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | £713M | £713M | £673M | £639M | £589M |
| Revenue growth | — | +6% | +5% | +8% | — |
| Gross profit | £290M | £290M | £260M | £244M | £236M |
| EBITDA | £140M | £140M | £136M | £126M | £125M |
| Net income | £17.3M | £17.3M | £19.3M | £6.20M | £41.9M |
| Free cash flow | £42.8M | £42.8M | £55.7M | £28.3M | £42.2M |
| Capital expenditure | £36.4M | £36.4M | £34.2M | £43.1M | £45.7M |
| Total debt | n/a | £320M | £249M | £288M | £199M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CVSG.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.8% | +1.6% | 5th highest of 20 |
| 6-month return | +16.8% | -3.8% | 4th highest of 20 |
| Distance from 52-week high | -2.7% | -21.9% | 2nd highest of 21 |
| Revenue growth (TTM) | +5.9% | +13.8% | 8th lowest of 21 |
| Operating margin | 10.6% | 10.0% | 10th highest of 21 |
| Forward P/E | 14.6× | 30.6× | 2nd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 14.2% | 11.8% | 7th most demanding of 15 |
| Growth delivered (Del g) | +6.9% | +10.3% | 3rd lowest of 15 |
| Hurdle (Req g minus delivered) | +7.3 pp | -0.3 pp | 6th most demanding of 15 |
| ROIC minus cost of capital | -1.0 pp | -2.2 pp | 9th highest of 21 |
| EV / EBITDA | 8.8× | 18.3× | 3rd cheapest of 16 |
| Net debt / EBITDA | 2.2× | 2.5× | 9th least indebted of 17 |
| Bond spread | 115 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CVS CVSG.L | United Kingdom | $1.22B | +17% | +6% | 11% | 14.6× | 14.2% | +6.9% |
| Raffles Medical BSL.SI | Singapore | $1.23B | -13% | -3% | 11% | 27.1× | -2.7% | +6.1% |
| Spire Healthcare SPI.L | United Kingdom | $1.31B | +11% | +2% | 8% | 25.1× | 10.0% | +11.4% |
| Yatharth Hospital and Trauma Care Services YATHARTH.NS | India | $1.13B | +31% | +50% | 16% | 49.4× | n/a | n/a |
| Sanbo Hospital Management 301293.SZ | China | $1.35B | -29% | +17% | 6% | 135.5× | n/a | n/a |
| Park Medi World PARKHOSPS.NS | India | $1.10B | -4% | +21% | 21% | 30.6× | 22.1% | +10.2% |
| Rainbow Childrens Medicare RAINBOW.NS | India | $1.37B | -7% | +23% | 22% | 40.4× | 30.7% | +21.2% |
| Rhon-klinikum RHK.DE | Germany | $1.06B | +15% | +4% | -51% | 22.5× | n/a | n/a |
| Aevis Victoria AEVS.SW | Switzerland | $1.43B | +8% | +15% | -6% | 106.8× | 26.5% | +10.2% |
| Xi'an International Medical Investment 000516.SZ | China | $1.46B | -2% | -1% | -2% | n/a | 12.7% | +20.6% |
| Jupiter Life Line Hospitals JLHL.NS | India | $1.01B | +9% | +17% | 16% | 48.8× | n/a | n/a |
| Clinica Baviera CBAV.MC | Spain | $1.01B | +2% | +11% | 20% | 20.1× | 2.3% | +19.7% |
| Ramsay Generale de Sante GDS.PA | France | $969M | -25% | +3% | 4% | n/a | 6.1% | +6.0% |
| Paras Healthcare PARASHLTH.NS | India | $962M | n/a | +24% | 11% | n/a | n/a | n/a |
| HealthCare Global Enterprises HCG.NS | India | $955M | -7% | +13% | 8% | 88.8× | n/a | n/a |
| Sienna Senior Living SIA.TO | Canada | $1.58B | -8% | +15% | 10% | 40.9× | 18.9% | +8.6% |
| Thomson Medical A50.SI | Singapore | $923M | -18% | +6% | 10% | n/a | 21.2% | +11.8% |
| Huaxia Eye Hospital 301267.SZ | China | $1.78B | -18% | +2% | 15% | 23.5× | 2.1% | +10.4% |
| Extendicare EXE.TO | Canada | $1.91B | -16% | +36% | 9% | 19.3× | 10.8% | +8.5% |
| Kovai Medical Center & Hospital KOVAI.NS | India | $759M | +22% | +17% | 21% | n/a | 17.4% | +18.1% |
| Ardent Health ARDT | United States | $2.03B | +52% | +2% | 5% | 11.9× | -1.7% | +8.7% |
CVS has 2 bonds outstanding with $767M face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 6.33%, a spread of 115 bp over government bonds.